Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?

JAMA Oncol. 2016 Jun 1;2(6):721-2. doi: 10.1001/jamaoncol.2016.0094.

Authors

Charles D Blanke¹, Ronald P DeMatteo²

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
² Division of General Surgical Oncology, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.

PMID: 27031092
DOI: 10.1001/jamaoncol.2016.0094

No abstract available

MeSH terms

Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / immunology
Gastrointestinal Stromal Tumors / pathology
Humans
Imatinib Mesylate / therapeutic use*
Medication Therapy Management / trends
Molecular Targeted Therapy*

Substances

Imatinib Mesylate